Revolution Medicines Inc.’s KRAS inhibitor, Rasonque (daraxonrasib), received a thumbs-up from the EMA’s Committee for ...
Estuary Biotherapeutics Inc. emerged from stealth with a $93 million series A financing led by RA Capital Management to develop gene therapies to treat autosomal dominant polycystic kidney disease ...
Life sciences investors are raising billions of dollars in fresh capital, with a cluster of new funds and acquisition vehicles positioning specialist firms for more biotech company formation and ...
Biopharma deals, excluding M&As, reached $224.91 billion in the first nine months of 2026, up 5% from $213.62 billion during the same period in 2025. The year-to-date total was the highest in BioWorld ...
A consortium funded by the National Institutes of Health (NIH) has unveiled the most comprehensive map of somatic mosaicism ...
The complexity of osteoarthritis (OA) pain and the limitations associated with long-term opioid therapy have prompted interest in alternative analgesic strategies. Researchers at the Spanish National ...
Expression Therapeutics Inc. has been awarded a Small Business Innovation Research (SBIR) phase II grant of over $2 million by the NIH’s National Cancer Institute to advance ET-501, its ...
Estuary Biotherapeutics Inc. has launched with $103 million in total committed financing that will support advancement of the ...
Impaired brain-derived neurotrophic factor (BDNF)-TrkB signaling has been implicated in a range of neurological and neuropsychiatric disorders. Researchers from Pangea Bio reported the development of ...
T cells as potent killers of small-cell lung cancer, with their genetic signature potentially revealing patients who could ...
About two years after launching, RNAi-focused City Therapeutics Inc., a company co-founded by former Alnylam Pharmaceuticals Inc. founder and CEO John Maraganore, raised $200 million through an IPO to ...
CSPC Pharmaceutical Group Ltd. has obtained two separate clinical trial approvals from China’s National Medical Products Administration (NMPA) for SYS-6088 injection for advanced or metastatic solid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results